BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 7.58 USD -1.04% Market Closed
Market Cap: 1.6B USD

Wall Street
Price Targets

BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc

Wall Street analysts forecast BCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCRX is 21.05 USD with a low forecast of 9.09 USD and a high forecast of 31.5 USD.

Lowest
Price Target
9.09 USD
20% Upside
Average
Price Target
21.05 USD
178% Upside
Highest
Price Target
31.5 USD
316% Upside
BioCryst Pharmaceuticals Inc Competitors:
Price Targets
MGX
Metagenomi Inc
447% Upside
TGTX
TG Therapeutics Inc
41% Upside
QTTB
Homology Medicines Inc
264% Upside
ARX
Aroa Biosurgery Ltd
29% Upside
IMMX
Immix Biopharma Inc
11% Upside
EVAX
Evaxion Biotech A/S
95% Upside
ALXO
ALX Oncology Holdings Inc
101% Upside
CVAC
CureVac NV
7% Downside

Revenue
Forecast

Revenue Estimate
BioCryst Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for BioCryst Pharmaceuticals Inc's revenue is 27%. The projected CAGR for the next 3 years is 18%.

27%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
BioCryst Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
BioCryst Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BCRX's stock price target?
Price Target
21.05 USD

According to Wall Street analysts, the average 1-year price target for BCRX is 21.05 USD with a low forecast of 9.09 USD and a high forecast of 31.5 USD.

What is BioCryst Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%

For the last 13 years the compound annual growth rate for BioCryst Pharmaceuticals Inc's revenue is 27%. The projected CAGR for the next 3 years is 18%.

Back to Top